Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group

Inclusion Criteria: * Diagnosed with type 2 diabetes, either newly diagnosed with at least 2 months of diet or on OAD monotherapy for at least 3 months * Body Mass Index (BMI): 24-35 kg/m\^2 inclusive Exclusion Criteria: * SUBJECTS WITH TYPE 2 DIABETES * Receipt of any investigational drug within three months prior to this trial * Recurrent severe hypoglycemia as judged by the investigator * Cardiac disease * Use of any drug (except an OAD (oral anti-diabetic drug)) that in the investigator's opinion could interfere with the blood glucose level * Haemoglobin maximum 10 g/L * HbA1c above 12% * Loss of more than 400 mL blood during the 3 months prior to trial start * HEALTHY SUBJECTS * Receipt of any investigational drug within 3 months prior to this trial * Clinically relevant cardiac disease or any clinically significant abnormal ECG (electrocardiogram) * Use of any drug that in the investigator's opinion could interfere with the blood glucose level * Haemoglobin max. 10 g/L * HbA1c at least 6%